PENNISI, Grazia
 Distribuzione geografica
Continente #
NA - Nord America 1.065
EU - Europa 424
AS - Asia 158
AF - Africa 8
OC - Oceania 6
SA - Sud America 4
Totale 1.665
Nazione #
US - Stati Uniti d'America 1.063
IT - Italia 269
SG - Singapore 59
DE - Germania 53
CN - Cina 47
HK - Hong Kong 29
GB - Regno Unito 25
IN - India 15
FI - Finlandia 11
IE - Irlanda 10
RO - Romania 10
SE - Svezia 9
BE - Belgio 8
FR - Francia 7
AU - Australia 6
RU - Federazione Russa 6
CI - Costa d'Avorio 5
UA - Ucraina 4
CZ - Repubblica Ceca 3
KR - Corea 3
AT - Austria 2
CA - Canada 2
CH - Svizzera 2
ES - Italia 2
IR - Iran 2
JP - Giappone 2
PE - Perù 2
BR - Brasile 1
CL - Cile 1
DK - Danimarca 1
EG - Egitto 1
MA - Marocco 1
NL - Olanda 1
NO - Norvegia 1
TR - Turchia 1
ZA - Sudafrica 1
Totale 1.665
Città #
Chandler 179
Fairfield 115
Ashburn 105
Ann Arbor 63
Palermo 63
Woodbridge 59
Seattle 41
New York 38
Singapore 38
Houston 37
Wilmington 37
Cambridge 31
Medford 29
Central 26
Altamura 25
Des Moines 23
Ludwigshafen am Rhein 21
Princeton 21
Rome 21
Lawrence 19
Santa Clara 19
San Diego 18
Beijing 12
Milan 12
Washington 11
Dublin 10
Lappeenranta 9
Brussels 8
London 8
San Paolo di Civitate 8
Aragona 6
Boardman 6
Bremen 6
Mussomeli 6
Pune 6
Abidjan 5
Nanjing 5
Barcellona Pozzo di Gotto 4
Como 4
Gothenburg 4
Busto Arsizio 3
Dallas 3
Gradara 3
Kilburn 3
Kumar 3
Los Angeles 3
Nanchang 3
Oakland 3
Olomouc 3
Shenyang 3
Shenzhen 3
Signal Mountain 3
Sydney 3
Venice 3
Zhengzhou 3
Bari 2
Bernareggio 2
Bollate 2
Brescia 2
Buonconvento 2
Chennai 2
Chicago 2
Council Bluffs 2
Dearborn 2
Ficarazzi 2
Frankfurt am Main 2
Guangzhou 2
Helsinki 2
Hong Kong 2
Karaikudi 2
Krefeld 2
Messina 2
Misterbianco 2
Parma 2
Potenza 2
Ravanusa 2
Salemi 2
Seongnam 2
Seville 2
Southwark 2
Tokyo 2
Xi'an 2
Aversa 1
Aylesbury 1
Bad Durrheim 1
Bethesda 1
Bobingen 1
Bologna 1
Brandenburg 1
Campobasso 1
Carini 1
Casablanca 1
Castelbuono 1
Catania 1
Changsha 1
Coimbatore 1
Columbus 1
Comitini 1
Esslingen am Neckar 1
Forest City 1
Totale 1.275
Nome #
Antidiabetic drugs in NAFLD: The accomplishment of two goals at once? 164
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 131
Pharmacological therapy of non-alcoholic fatty liver disease: What drugs are available now and future perspectives 115
The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: Screening issue and future perspectives 110
Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis 96
MAFLD: a multisystem disease 88
IMPACT OF NON-ALCOHOLIC FATTY LIVER DISEASE ON CARDIOVASCULAR RISK IN A GENERAL POPULATION 83
IMPACT OF NON-ALCOHOLIC FATTY LIVER DISEASE ON CARDIOVASCULAR RISK IN A GENERAL POPULATION 77
Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population 69
A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease 68
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach? 56
Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver disease 52
Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis 51
PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease 46
Biochemical biomarkers of NAFLD/NASH 43
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes 40
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease 40
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices 39
Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease 37
A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease 37
Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD 36
PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD 35
Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease 35
Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease 34
SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease 32
Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis 31
AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD 28
null 27
Heart rate variability is associated with disease severity and portal hypertension in cirrhosis 25
NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease 23
THE ROLE OF TRANSIENT ELASTOGRAPHY IN NAFLD 19
The relevance of noninvasive tools to assess fibrosis in non-alcoholic fatty liver disease 18
Impact of direct-acting antivirals (DAAs) on cardiovascular diseases in patients with chronic hepatitis C 18
Inflammation and autonomic balance in cirrhosis: Association between sympathetic nervous system and osteopontin, interleukin-22, interleukin-6 and interleukin-1Ra concentrations according to portal hypertension and disease severity 16
ANGPTL3 Downregulation Increases Intracellular Lipids by Reducing Energy Utilization 14
The PD-1/PD-L1 Axis in the Biology of MASLD 12
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis 9
Point-of-Care Noninvasive Prediction of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease 9
Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women 9
Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease 9
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study 8
Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease 4
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease 1
Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria 1
Clinical outcomes of MAFLD versus NAFLD: A meta-analysis of observational studies 1
Are we ready for genetic testing in metabolic dysfunction-associated steatotic liver disease? 1
Evaluation of ChatGPT as a Counselling Tool for Italian-Speaking MASLD Patients: Assessment of Accuracy, Completeness and Comprehensibility 1
Corrigendum to “SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease” [J Hepatol 80 (2024) 10-19, (S0168827823051474), (10.1016/j.jhep.2023.09.020)] 1
Mitochondrial amidoxime-reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome 1
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease 1
Prevalence and Determinants of Liver Disease in Relatives of Italian Patients With Advanced MASLD 1
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD) 1
Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis 1
Correction to: Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women (Nature Medicine, (2023), 29, 10, (2643-2655), 10.1038/s41591-023-02553-8) 1
Totale 1.905
Categoria #
all - tutte 11.453
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.453


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020168 0 0 1 22 9 39 19 15 25 12 25 1
2020/2021249 8 16 20 35 17 5 25 12 23 29 40 19
2021/2022286 12 26 22 11 6 10 7 48 25 33 36 50
2022/2023609 35 94 4 74 55 70 31 95 73 7 44 27
2023/2024441 18 38 25 33 32 132 45 10 10 28 20 50
2024/2025118 28 54 36 0 0 0 0 0 0 0 0 0
Totale 1.905